Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis

Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis

John R Hurst,1 Maria Dilleen,2 Kevin Morris,3 Siân Hills,3 Birol Emir,4 Rupert Jones5 1UCL Respiratory, University College London, London, UK; 2Statistics, Global Product Development, Pfizer, Tadworth, UK; 3Medical Affairs, Pfizer, Tadworth, UK; 4Biostatistics, Global Product Development,...

Full description

Bibliographic Details
Main Authors:	Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-03-01
Series:	International Journal of COPD
Subjects:	inhaled corticosteroid treatment step-up GOLD 2017 grouping patient over-treatment
Online Access:	https://www.dovepress.com/factors-influencing-treatment-escalation-from-long-acting-muscarinic-a-peer-reviewed-article-COPD

Similar Items

The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study
by: Singh D, et al.
Published: (2017-11-01)

Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences
by: Lutter JI, et al.
Published: (2021-04-01)

When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals
by: Gaduzo S, et al.
Published: (2019-02-01)

January 2015 Tucson pulmonary journal club: withdrawal of inhaled glucocorticoids in COPD
by: Wong C, et al.
Published: (2015-02-01)

The Association Between Eosinophil Variability Patterns and the Efficacy of Inhaled Corticosteroids in Stable COPD Patients
by: Yoon JK, et al.
Published: (2020-08-01)

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
by: Avdeev S, et al.
Published: (2019-06-01)

Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry
by: Kobayashi S, et al.
Published: (2018-12-01)

Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014
by: Josefin Sundh, et al.
Published: (2017-01-01)

Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study
by: Helgo Magnussen, et al.
Published: (2021-01-01)

Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis
by: Cheng SL
Published: (2018-09-01)

Surfactant therapy as a part of comprehensive treatment of asthma patients. Impact on clinical signs and external respiration rates
by: O. A. Rozenberg, et al.
Published: (2018-10-01)

Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids
by: Kanemitsu, Yoshihiro
Published: (2015)

Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts
by: Cheng SL, et al.
Published: (2016-09-01)

Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies
by: Lodise TP, et al.
Published: (2020-11-01)

Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
by: Akira Koarai, et al.
Published: (2021-06-01)

Influence of polymorphism of the gene of inducible NO-synthase on the achievement of control of bronchial asthma in children against the background of inhalation corticosteroid therapy
by: I. Yu. Smirnova, et al.
Published: (2009-08-01)

Reduction of Eosinophils in Small Airways by Inhaled Steroids is Insufficient in Patients with Adult Asthma
by: Hiroshi Tanaka, et al.
Published: (2006-01-01)

The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study
by: Hsieh MJ, et al.
Published: (2018-09-01)

Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies
by: Hollis S, et al.
Published: (2017-04-01)

Characterization of COPD Admissions During the First COVID-19 Outbreak
by: Cosio BG, et al.
Published: (2021-06-01)

Inhaled Corticosteroids in COPD: Trying to Make a Long Story Short
by: Tantucci C, et al.
Published: (2020-04-01)

Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
by: Janson C, et al.
Published: (2017-10-01)

The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) study
by: Wang CY, et al.
Published: (2016-11-01)

Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study
by: Bloom CI, et al.
Published: (2020-04-01)

Low incidence of pneumonia in COPD patients treated with inhaled corticosteroids undergoing pulmonary rehabilitation
by: Erminia Ridolo, et al.
Published: (2018-05-01)

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)
by: Beeh KM, et al.
Published: (2016-02-01)

Comparison of Characteristics Between ICS-Treated COPD Patients and ICS-Treated COPD Patients with Concomitant Asthma: A Study in Primary Care
by: Savran O, et al.
Published: (2020-04-01)

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
by: Micheletto C, et al.
Published: (2019-09-01)

Inhaled corticosteroids can reduce osteoporosis in female patients with COPD
by: Liu SF, et al.
Published: (2016-07-01)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
by: D’Urzo AD, et al.
Published: (2018-04-01)

Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting
by: Whittaker HR, et al.
Published: (2019-05-01)

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
by: Vestbo J, et al.
Published: (2019-04-01)

Withdrawal of Inhaled Corticosteroids in Patients with COPD – A Prospective Observational Study
by: Nielsen AO, et al.
Published: (2021-03-01)

Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations
by: Usmani OS, et al.
Published: (2020-10-01)

Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort
by: Le LAK, et al.
Published: (2019-07-01)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
by: Singh D, et al.
Published: (2019-02-01)

Effect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPD
by: Yamauchi Y, et al.
Published: (2016-06-01)

Blood eosinophil count in patients with COPD on inhaled corticosteroids in comparison with healthy smoker and nonsmoker controls
by: Noha Othman Ahmed, et al.
Published: (2021-01-01)

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking
by: Ariel A, et al.
Published: (2017-12-01)

A Belgian survey on the diagnosis of asthma–COPD overlap syndrome
by: Cataldo D, et al.
Published: (2017-02-01)

Cannot write session to /tmp/vufind_sessions/sess_o17hf6kq2qav1qno9sjin0g2lg